BusinessUS FDA Issues Two Observations to Dr. Reddy’s Andhra Facility
The US Food and Drug Administration (FDA) issued two observations to Dr. Reddy’s Laboratories' FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh, following a pre-approval inspection from October 5-7, 2026. The company stated it will address the observations within the required timeline. Dr. Reddy’s shares fell 1.86% to ₹1,180 on the BSE after the announcement.
Hindu Business··Pydibhimavaram

